AIR-CF1: Lung Function Clinical Data

CAYSTON significantly improved lung function

Mean percent change in FEV1 (L) was a prespecified secondary endpoint in AIR-CF1.1 Click here to review the study design.

CAYSTON demonstrated a significant improvement in FEV1 (L) lung function with a placebo-adjusted treatment effect of 10% (95% CI: 6%, 14%) on Day 28.

Improvements in FEV1 were comparable between adult and pediatric patients1

CAYSTON AIR-CF1: Lung Function
Kevin, treated with CAYSTON

“When I'm on CAYSTON, I notice a positive difference in my coughing and see a boost in my lung function.”

–Kevin, age 43, TREATED WITH CAYSTON

Learn About Disease Severity
NEXT